Literature DB >> 15138935

Pathology of parainfluenza virus infection in patients with congenital immunodeficiency syndromes.

John F Madden1, James L Burchette, Laura P Hale.   

Abstract

Infection with parainfluenza virus typically produces a mild, self-limited upper respiratory infection. However, parainfluenza infections have become increasingly recognized as a source of severe morbidity and mortality in immunocompromised patients. In this retrospective study we identified 6 patients with congenital immunodeficiency and positive respiratory cultures for parainfluenza virus who died and underwent complete autopsy. Tissues obtained at autopsy were studied using hematoxylin and eosin-stained sections, immunoperoxidase staining for parainfluenza virus, and in selected cases, electron microscopy. All 6 patients exhibited typical cytopathic effects of parainfluenza virus, including giant cell formation, in lung and/or bronchial tissues. Parainfluenza virus infection was also documented by giant cell formation and immunohistochemistry in the pancreas (in 3 of 6 patients) and the kidney or bladder (in 2 of 4 patients). Anti-parainfluenza antibody also specifically reacted with cells in the gastrointestinal tract (in 2 of 4), spleen (in 4 of 6), thymus and/or lymph nodes (in 4 of 4), and small blood vessels in various organs (in 4 of 6). Pancreatic, bladder, colon, and thymic epithelial cell lines were susceptible to experimental infections with clinical isolates of parainfluenza virus type 3 in vitro. Parainfluenza virus infection was serious in patients with congenital immunodeficiencies, contributing directly to death in 5 of the 6 patients studied. Because this virus is capable of infecting tissues in the gastrointestinal and urinary systems as well as in the respiratory tract, body secretions and fluids from each of these locations should be considered potentially infectious.

Entities:  

Mesh:

Year:  2004        PMID: 15138935     DOI: 10.1016/j.humpath.2003.11.012

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  8 in total

1.  Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Authors:  Makiko Watanabe; Vasiliy P Mishin; Scott A Brown; Charles J Russell; Kelli Boyd; Y Sudhakara Babu; Garry Taylor; Xiaoping Xiong; Xiaowei Yan; Allen Portner; Irina V Alymova
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

Review 2.  Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.

Authors:  Henrick Schomacker; Anne Schaap-Nutt; Peter L Collins; Alexander C Schmidt
Journal:  Curr Opin Virol       Date:  2012-03-03       Impact factor: 7.090

3.  Local production of inflammatory mediators during childhood parainfluenza virus infection.

Authors:  Rana E El Feghaly; Lindsay McGann; Cynthia A Bonville; Patrick J Branigan; Manika Suryadevera; Helene F Rosenberg; Joseph B Domachowske
Journal:  Pediatr Infect Dis J       Date:  2010-04       Impact factor: 2.129

Review 4.  Antivirals targeting paramyxovirus membrane fusion.

Authors:  Erik M Contreras; Isaac Abrrey Monreal; Martin Ruvalcaba; Victoria Ortega; Hector C Aguilar
Journal:  Curr Opin Virol       Date:  2021-09-27       Impact factor: 7.090

Review 5.  Detection of respiratory viruses by molecular methods.

Authors:  James B Mahony
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

6.  Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.

Authors:  Anne Schaap-Nutt; Margaret A Scull; Alexander C Schmidt; Brian R Murphy; Raymond J Pickles
Journal:  Vaccine       Date:  2010-02-20       Impact factor: 3.641

7.  Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium.

Authors:  Anne Schaap-Nutt; Rachael Liesman; Emmalene J Bartlett; Margaret A Scull; Peter L Collins; Raymond J Pickles; Alexander C Schmidt
Journal:  Virology       Date:  2012-09-07       Impact factor: 3.616

8.  Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase.

Authors:  Robert M Cox; Julien Sourimant; Mart Toots; Jeong-Joong Yoon; Satoshi Ikegame; Mugunthan Govindarajan; Ruth E Watkinson; Patricia Thibault; Negar Makhsous; Michelle J Lin; Jose R Marengo; Zachary Sticher; Alexander A Kolykhalov; Michael G Natchus; Alexander L Greninger; Benhur Lee; Richard K Plemper
Journal:  Nat Microbiol       Date:  2020-07-13       Impact factor: 17.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.